Medsintez Plant Was Awarded the Title of National Champion

In May 2025, pharmaceutical plant Medsintez Plant LLC joined the leading enterprises that were awarded the status of National Champion based on the results of a comprehensive expert selection. Getting the status of National Champion is a significant event for Medsintez Plant, which emphasizes its contribution to the development of the pharmaceutical industry and strengthening the drug safety of Russia.

Photo: Maxim Stulov / Vedomosti

The status of National Champion is awarded based on the results of an expert selection, which evaluates the financial stability, innovation and contribution of the company to the economy. This selection involved 80 organizations that had already achieved significant results in their field: IT, pharmaceuticals, production of unmanned aerial vehicles and digital control systems. However, only 18 of them were able to obtain the status of National Champion.

Photo: Andrey Gordeev / Vedomosti

This project is of particular importance because it confirms the Medsintez Plant’s commitment to development, growth, and creation of innovative products.

Medsintez Plant LLC is a Russian pharmaceutical plant specializing in the full-cycle development and production of medical drugs. As a key player in the pharmaceutical industry, it focuses on ensuring Russia's drug safety while actively implementing advanced technologies for a wide range of vital and innovative medical drugs targeting viral infections, chronic diseases (e.g., diabetes), women's health, and other critical areas.

The National Champion status underscores the strategic importance of Medsintez Plant LLC for the Russian pharmaceutical industry, particularly strengthening the position of its flagship drug—Triazavirin®.

This antiviral drug—developed through years of Russian scientific research—occupies a central place in the plant's portfolio. Having proven its effectiveness in clinical practice, it has become an important tool in the treatment and prevention of influenza, acute respiratory viral infections (ARVI) and other RNA viral infections in adults, which is confirmed by its inclusion in the federal clinical guidelines of the Russian Ministry of Health.

The successful post-registration use of the drug in adults and the growing interest of pediatricians justified the development of a new 100mg pediatric dosage of the drug.

The Medsintez Plant is currently awaiting the completion of regulatory procedures by the Russian Ministry of Health to obtain a marketing authorisation. Soon, pediatricians will have access to a direct-acting, safe, and effective treatment for pediatric ARVI targeting the root cause of the disease.

Medsintez Plant LLC is an enterprise that symbolizes innovation and leadership in producing vital medicines ensuring the health of millions of Russians. Thanks to its unique manufacturing process and stringent quality control, the plant produces world-class drugs, among which insulin and follicle-stimulating hormone (FSH) occupy a special place.

Insulin is an important component of diabetes treatment, providing reliable support to patients who need effective blood glucose control. Rosinsulin® is distinguished by quality assurance at every stage of production, offering high purity and a minimal risk of side effects, due to which it enjoys the well-deserved trust of doctors and patients.

Rosinsulin® is a next-generation medical drug that meets global standards, fully replacing imported equivalents for personalized diabetes therapy.

Follicle-stimulating hormone Primapur® effectively treats human infertility, enhancing conception success. It is produced through rigorously controlled technologies and helps families find the joy of motherhood and fatherhood.

Among reproductive technologies, the recombinant FSH Primapur® is an essential component of IVF programs, having a high degree of efficiency due to proven clinical effectiveness.

The products of Medsintez Plant LLC guarantee safety, effectiveness, and availability of vital medical drugs to every patient in Russia. Advanced technology, skilled personnel, and strict adherence to international standards ensure its products a reliable choice for healthcare professionals and patients throughout the country.

Achieving the National Champion status is a well-deserved recognition of the enterprise's contribution to strengthening the country's drug safety and the development of the domestic pharmaceutical industry. For years, the Medsintez Plant has pursued a consistent strategy of end-to-end innovative medical drug production—from R&D to finished product output.